Literature DB >> 8752934

Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes.

S A Thomson1, S L Elliott, M A Sherritt, K W Sproat, B E Coupar, A A Scalzo, C A Forbes, A M Ladhams, X Y Mo, R A Tripp, P C Doherty, D J Moss, A Suhrbier.   

Abstract

Development of epitope-based CD8 alpha beta CTL vaccines requires effective strategies for codelivery of large numbers of individual epitopes. We have designed an artificial "polyepitope" protein containing 10 contiguous minimal CTL epitopes, which were restricted by five MHC alleles and derived from five viruses, a parasite, and a tumor model. A recombinant vaccinia virus coding for this protein was capable of inducing MHC-restricted primary CTL responses to all 10 epitopes. Mice immunized with this recombinant vaccinia showed protection against murine cytomegalovirus, Sendai virus, and a tumor model. This simple generic approach to multiepitope delivery should find application in CTL-based vaccine design.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752934

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.

Authors:  A M Doling; J D Ballard; H Shen; K M Krishna; R Ahmed; R J Collier; M N Starnbach
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 3.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

4.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

5.  Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1.

Authors:  S I Bazhan; P A Belavin; S V Seregin; N K Danilyuk; I N Babkina; L I Karpenko; N A Nekrasova; L R Lebedev; A P Agafonov; G M Ignat'ev; A A Il'ichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

6.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

7.  A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.

Authors:  L L An; J L Whitton
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles.

Authors:  C L Day; A K Shea; M A Altfeld; D P Olson; S P Buchbinder; F M Hecht; E S Rosenberg; B D Walker; S A Kalams
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 9.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

10.  Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.

Authors:  Inge E A Flesch; Wai-Ping Woo; Yang Wang; Vijay Panchanathan; Yik-Chun Wong; Nicole L La Gruta; Tania Cukalac; David C Tscharke
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.